To reverse the suppressive tumor microenvironment, some study developed gene modified T-cells bearing a chimeric receptor in which activating receptor NKG2D fused to intracellular domains of 4-1BB and CD3z (NKG2D CAR) (162). Here, KLRK1 is linked to neoplasm.